NASDAQ$TRVI
Trevi Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close
Briefing
Trevi Therapeutics Inc reported a net loss of $12.3 million for the second quarter of 2025.
Trevi Therapeutics Inc, a clinical-stage biopharmaceutical company, reported operating expenses of $13.7 million for Q2 2025, resulting in a net loss of $12.3 million or $0.09 per share. The company had cash and cash equivalents of $117.1 million and total assets of $208.3 million at quarter end. No revenue was generated as the company continues development of Haduvio without approved products.
- Net loss of $12.3 million for the three months ended June 30, 2025, compared to $12.4 million in the prior year period.
- Research and development expenses decreased to $9.4 million from $10.0 million year-over-year.
- Cash and cash equivalents increased to $117.1 million, supported by equity offerings.
- Company remains focused on Phase 3 program and other trials for Haduvio in chronic cough indications.
Headline financials
Revenue & EPS history
Trevi Therapeutics Inc · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
+0.7%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+8.6%
Avg return
30 days after
42%
5 / 12 earnings
Positive
+8.1%
Q2 2024
Best reaction
-4.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +2.0% | +0.9% | -3.1% | |
| Q4 2025 | -4.5% | -3.8% | +36.1% | |
| Q3 2025 | -3.3% | -4.6% | +7.8% | |
| Q1 2025 | -0.9% | -3.1% | +6.0% | |
| Q3 2024 | +2.6% | +1.7% | -8.6% | |
| Q2 2024 | +8.1% | +4.2% | +13.9% | |
| Q1 2024 | -1.4% | -7.1% | -16.0% | |
| Q3 2023 | +0.0% | -6.0% | -16.1% | |
| Q2 2023 | +4.8% | +3.5% | +0.4% | |
| Q1 2023 | +0.0% | -2.2% | +85.9% | |
| Q3 2022 | +0.0% | +14.0% | +20.7% | |
| Q2 2022 | +0.2% | -13.1% | -23.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro